Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107
PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:
American Association for Cancer Research – Immuno-Oncology
Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025)Poster entitled: “Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"
The abstract will be made available on INOVIO’s website following the conference.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.comInvestors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immune-response-data-for-ino-3107-to-be-presented-as-a-poster-at-american-association-for-cancer-research-immuno-oncology-aacr-io-conference-302372309.html
SOURCE INOVIO Pharmaceuticals, Inc.
